|
|
 |
|
Viewing report
|
|
|
|
Commercial Insight: Cytotoxic Therapy Cancer Brands - Looming Patent Expiries Limit Market Growth
Datamonitor, July 2008, Pages: 259
Cytotoxic therapies are the second largest class of cancer therapeutics, generating branded drug sales of over $10 billion in the seven major pharmaceutical markets in 2007. Patent expiries for a number of agents that have achieved blockbuster sales over the years, means that the market continues to attract a considerable amount of generic competition.
Scope
- Analysis of the performance of each of the cytotoxic therapy cancer brands in the seven major markets, forecast to 2017
- Analysis and segmentation of the market at various levels including drug class, indication, company and sales growth rate
- Assessment of the leading cancer brands and drug classes to identify key success factors within this sector
- Quantification of the market size of the cytotoxic therapy cancer brands in the seven major pharmaceutical markets with the rest of world markets
Highlights of this title
The cytotoxic therapy cancer brands market is currently worth just over $10 billion and is forecast to grow to sales of almost $15 billion. The launch of the antimetabolite brands, Dacogen (decitabine; Eisai/Johnson & Johnson) and Vidaza (azacitadine; Celgene) in the EU and Japanese markets contributes to this growth.
As a class, DNA-interactive cytotoxic therapy cancer brands contributed the highest proportion of sales in 2007 with $4.3 billion. This is in part, driven by the sales of Eloxatin (oxaliplatin; Sanofi-Aventis) and Camptosar. However, by 2017, the antimetabolite brands class are set to overtake.
Twenty four companies are involved in the development of currently approved cytotoxic therapy cancer brands, over half of which have more than one cytotoxic brand on the market. Sanofi-Aventis leads with four out of the 25 cytotoxic brands marketed, which made a collective $4,176m for the company in the seven major markets in 2007.
Key reasons to purchase this title
- Quantify the performance of each of the marketed cytotoxic therapy cancer brands in the seven major markets over the period 2007 to 2017
- Acquire a detailed account of cytotoxic therapy cancer brand dynamics and the events that drive and limit their market growth
- Benchmark the cytotoxic therapy cancer brands against their generics and rest of class and align their 7MM performance with a rest of world snapshot
Customers who bought this item also bought
Commercial Insight: Targeted Therapy Cancer Brands - High Growth Market will see Eight New Blockbusters by 2017
Cytotoxic Therapies Market Forecast
Antihormonal Therapy Cancer Brands - Careful Lifecycle Management Needed to Preserve Brand Dominance
Forecast Insight: Top 20 Cancer Therapy Brands
Commercial Insight: Cytotoxic Therapies - Market growth will slow due to increasing genericization
Forecast Insight: Depression - Generic Induced Brand Erosion Leads to Market Decline
Commercial Insight: Top 20 Cancer Therapy Brands - Sales of targeted therapies overtake cytotoxics in 2006
Oncology Roadmap: Brand Spending Benchmarks and Market Forecast to 2013
Top 20 Therapy Cancer Brands - Key Brands Set to Consolidate Advantage as Competition Intensifies
Top 20 Cancer Therapy Brands Forecast
Commercial Insight: Insomnia Strong brand identity critical to differentiation in an increasingly crowded market
The Cancer Market Outlook to 2012
|
|
|
|
